Literature DB >> 1908091

Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

S J Devi1, J B Robbins, R Schneerson.   

Abstract

Meningitis and other systemic infections caused by group B Neisseria meningitidis and Escherichia coli K1 remain important problems. The capsular polysaccharides (CPs) of these pathogens (poly[(2----8)-alpha-N-acetylneuraminic acid] or poly(alpha 2-8NeuNAc] are identical and are virulence factors and protective antigens for both. CP vaccines for these pathogens are not available because poly(alpha 2-8NeuNAc) alone, as a complex or a conjugate, is poorly immunogenic. Because oligomers of poly(alpha 2-8NeuNAc) in fetal brain and other tissues bind antibodies in vitro, it has been suggested that antibodies to this CP might be pathologic. We synthesized conjugates of this CP with tetanus toxoid under conditions that avoid lactone formation. Using this scheme, we also synthesized conjugates of group C meningococcal CP (poly[(2----9)-alpha-N-acetylneuraminic acid] or poly(alpha 2-9NeuNAc] and of E. coli K92 CP [poly(alpha 2-8, alpha 2-9NeuNAc)]. When injected s.c. in saline into mice, conjugates of poly(alpha 2-8NeuNAc) or poly(alpha 2-9NeuNAc) elicited homologous antibodies. E. coli K92 conjugates elicited both poly(alpha 2-8NeuNAc) and poly(alpha 2-9NeuNAc) antibodies. Both components of the conjugates expressed T-dependent immunologic properties under conditions and dosages acceptable for clinical evaluation. Poly(alpha 2-8NeuNAc) antibodies elicited by the homologous or the K92 conjugates had lower binding activities at 37 degrees C than at 22 degrees C. "Natural" poly(alpha 2-8NeuNAc) antibodies were present in almost all matched pairs of human maternal and cord sera; most cord levels were higher than in corresponding maternal sera. These findings suggest that increased levels of poly(alpha 2-8NeuNAc) IgG antibodies elicited by our conjugates will confer protective immunity to group B meningococci and E. coli K1 and will not be pathologic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908091      PMCID: PMC52256          DOI: 10.1073/pnas.88.16.7175

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.

Authors:  B A Claesson; B Trollfors; T Lagergard; J Taranger; D Bryla; G Otterman; T Cramton; Y Yang; C B Reimer; J B Robbins
Journal:  J Pediatr       Date:  1988-05       Impact factor: 4.406

2.  Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  H J Jennings; R Roy; A Gamian
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

Review 3.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

4.  Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1.

Authors:  H J Jennings; A Gamian; F Michon; F E Ashton
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides.

Authors:  A Sutton; W F Vann; A B Karpas; K E Stein; R Schneerson
Journal:  J Immunol Methods       Date:  1985-10-10       Impact factor: 2.303

6.  Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo.

Authors:  K Saukkonen; M Haltia; M Frosch; D Bitter-Süerman; M Leinonen
Journal:  Microb Pathog       Date:  1986-02       Impact factor: 3.738

7.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.

Authors:  P Brandtzaeg; P Kierulf; P Gaustad; A Skulberg; J N Bruun; S Halvorsen; E Sørensen
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

8.  Determination of sialic acids by acidic ninhydrin reaction.

Authors:  K Yao; T Ubuka
Journal:  Acta Med Okayama       Date:  1987-12       Impact factor: 0.892

9.  Prevention and therapy of experimental Escherichia coli infection with monoclonal antibody.

Authors:  K S Kim; A S Cross; W Zollinger; J Sadoff
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

10.  Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.

Authors:  H V Raff; D Devereux; W Shuford; D Abbott-Brown; G Maloney
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

View more
  26 in total

1.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

2.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

4.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

5.  Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: towards an improved surveillance of meningococcal disease.

Authors:  J Andersen; L Berthelsen; I Lind
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

6.  Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes.

Authors:  J S Shin; J S Lin; P W Anderson; R A Insel; M H Nahm
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Authors:  Z Kossaczka; S Bystricky; D A Bryla; J Shiloach; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  The conformational properties of methyl alpha-(2,8)-di/trisialosides and their N-acyl analogues: implications for anti-Neisseria meningitidis B vaccine design.

Authors:  Austin B Yongye; Jorge Gonzalez-Outeiriño; John Glushka; Verena Schultheis; Robert J Woods
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

Review 9.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

10.  The changing epidemiology of invasive bacterial infections in Massachusetts children, 1984 through 1991.

Authors:  A M Loughlin; C D Marchant; S M Lett
Journal:  Am J Public Health       Date:  1995-03       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.